Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
6770 participants
OBSERVATIONAL
2025-08-11
2029-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
TB-QUEST is an ERC-funded epidemiological field study that aims to provide direct evidence of effective transmission from asymptomatic TB cases to their close contacts using advanced genomic methods, and to better characterize the asymptomatic stage of TB within the natural history of disease.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
TB QUEST is a prospective epidemiological field study designed to address several critical research gaps surrounding aTB. The overall aim of the study is to provide direct evidence of asymptomatic TB transmission, and to better characterize the asymptomatic TB stage within the natural history of disease. This project has four main objectives:
Objective 1: To provide direct evidence on the successful transmission of tuberculosis infection (leading to TB disease) by individuals diagnosed with aTB Objective 2: To ascertain the presence of typical TB symptoms in self-reported asymptomatic laboratory-confirmed TB patients Objective 3: To understand the factors associated with Mtb self-clearance or disease progression in patients with aTB Objective 4: To understand the characteristics and progression of non-infectious aTB
TB QUEST will recruit asymptomatic and symptomatic index TB cases as well as their close contacts, allowing for the observation of secondary (genomically-linked) cases and new infections while providing direct temporal characterization and directionality of TB transmission. In addition, TB QUEST nests three additional longitudinal assessments among individuals with aTB in order to ascertain presence of symptoms and assess their clinical trajectory.
The project is coordinated by the Barcelona Institute for Global Health (ISGlobal) in close collaboration with the Centro de Investigação em Saúde de Manhiça (CISM), located in the district of Manhiça, Mozambique, where all field work will be conducted. The district of Manhiça is a high TB/HIV burden area in Southern Mozambique, where the latest reported TB case notification is around 500 per 100,000 population and the prevalence of HIV in the adult population was 35%.
TB QUEST will conduct an initial cross-sectional assessment among PLHIV attending routine follow up visits in order to identify bacteriologically-confirmed asymptomatic and symptomatic TB cases. It follows with a nested prospective contact cohort study in which two cohorts of close-contacts exposed to the aTB and clinical TB cases, respectively, will be followed up periodically for 12 months. The project embeds three additional longitudinal assessments: a) one among both asymptomatic and symptomatic TB cases to objectively verify the presence of common TB symptoms, b) one among a proportion of aTB cases that will be closely monitored for radiological, microbiological and clinical changes to assess the trajectory of aTB, and c) one in which a subset of non-infectious aTB patients will be followed to observe its trajectory.
TB-QUEST will generate high-quality evidence to resolve the current hypotheses on aTB transmission. If aTB plays and important role in TB transmission, the current pillars of TB control will prove to be insufficient to achieve the reduction of TB incidence and mortality set by the international community. Thus, this proposal has the potential to represent a paradigm shift for TB control. The evidence derived from this study will challenge global symptom-driven case finding strategies, as well as the clinical management of aTB cases. Further, disentangling the evolution of aTB may allow for its inclusion as a primary endpoint in TB vaccine and drug trials, improving efficiency in future TB research and the development of new tools to fight the disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Asymptomatic
Contacts of bacteriologically-confirmed asymptomatic TB index cases
No interventions assigned to this group
Symptomatic
Contacts of bacteriologically-confirmed symptomatic TB index cases
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Documented HIV infection
3. Presenting at a health facility for routine HIV care
1. On ART for less than 6 months
2. No evidence of viral suppression
3. Documented CD4 count \>350 copies/ul
4. TB-suggestive x-ray
5. Verified absence of fever and cough, as ascertained through the symptom trackers
Contacts:
Exclusion Criteria
2. Pregnant women
3. Refusal to provide consent for study procedures
4. Contra-indication to any sampling procedure required by the study
1. Plans to migrate in the next 12 months
2. Pregnant women
3. Currently taking anti-tuberculosis treatment or preventive TB treatment
4. Contacts with co-prevalent TB identified at baseline
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Barcelona Institute for Global Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alberto Garcia-Basteiro
Research Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro de Investigação em Saúde de Manhiça (CISM)
Manhiça, Maputo Province, Mozambique
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Amuly Chilopola, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ERC-2023-STG-101117940
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
101117940
Identifier Type: -
Identifier Source: org_study_id